These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 23647483)

  • 21. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
    Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
    Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.
    Johnston K; Powell LC; Popoff E; L'Italien GJ; Pawinski R; Ahern A; Large S; Tran T; Jenkins A
    J Med Econ; 2024; 27(1):627-643. PubMed ID: 38590236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE
    Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Long-Term, Targeted OnabotulinumtoxinA versus Peripheral Trigger Site Deactivation Surgery for the Treatment of Refractory Migraine Headaches.
    Schoenbrunner AR; Khansa I; Janis JE
    Plast Reconstr Surg; 2020 Feb; 145(2):401e-406e. PubMed ID: 31985655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
    Khalil M; Zafar HW; Quarshie V; Ahmed F
    J Headache Pain; 2014 Sep; 15(1):54. PubMed ID: 25178393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
    Blumenfeld AM; Aurora SK; Laranjo K; Papapetropoulos S
    BMC Neurol; 2015 Jul; 15():100. PubMed ID: 26133547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.
    Rothrock JF; Bloudek LM; Houle TT; Andress-Rothrock D; Varon SF
    Headache; 2014; 54(10):1565-73. PubMed ID: 25298117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment.
    Brown JS; Papadopoulos G; Neumann PJ; Friedman M; Miller JD; Menzin J
    Headache; 2005 Sep; 45(8):1012-22. PubMed ID: 16109115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
    J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M; Halker R; Pozo-Rosich P; DeGryse R; Manack Adams A; Aurora SK
    J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
    Sussman M; Benner J; Neumann P; Menzin J
    Cephalalgia; 2018 Sep; 38(10):1644-1657. PubMed ID: 30142988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
    Lipton RB; Rosen NL; Ailani J; DeGryse RE; Gillard PJ; Varon SF
    Cephalalgia; 2016 Aug; 36(9):899-908. PubMed ID: 27288354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
    Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
    Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
    Walker A; Doyle S; Posnett J; Hunjan M
    BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT; Jaffri SF
    Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.